Autopsy report · NCT03549338

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

“Study was terminated due to administrative reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 3 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Symphogen A/S

Sponsor type

Industry

Conditions

Metastatic Colorectal Cancer; Colorectal Cancer Metastatic; Carcinoma

Interventions

Sym004; Futuximab; Modotuximab

Participants

2

Sites

18

Countries

Germany, Italy, Spain, United States

Trials that died the same way

• An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
  “Study was prematurely terminated due to administrative and strategic reasons” (90% match in meaning)
• Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer
  “Study was terminated due to lack of accrual” (88% match in meaning)
• Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
  “Study terminated for business reasons” (88% match in meaning)
• Measuring Relative Afferent Pupillary Defect
  “The study was terminated early for administrative reasons.” (88% match in meaning)
• Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
  “Study was terminated due to safety reason.” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.